Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
0(0%)
Results Posted
88%(7 trials)

Phase Distribution

Ph phase_1
2
25%
Ph phase_3
3
38%
Ph phase_2
1
13%
Ph phase_4
1
13%

Phase Distribution

2

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
3(42.9%)
Phase 4Post-market surveillance
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

8 of 8 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(8)

Detailed Status

Completed8

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (28.6%)
Phase 21 (14.3%)
Phase 33 (42.9%)
Phase 41 (14.3%)

Trials by Status

completed8100%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_3

Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients

NCT01174446
completedphase_1

Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients

NCT03186677
completed

Registry For Patients Treated With BeneFix In Usual Care Setting In Germany

NCT00714415
completedphase_2

Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia B

NCT03091751
completedphase_4

Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China

NCT02336178
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT01174446Phase 3

Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients

Completed
NCT03186677Phase 1

Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients

Completed
NCT00714415

Registry For Patients Treated With BeneFix In Usual Care Setting In Germany

Completed
NCT03091751Phase 2

Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia B

Completed
NCT02336178Phase 4

Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China

Completed
NCT02213250Phase 1

An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia B

Completed
NCT00866606Phase 3

Study Evaluating On-Demand Treatment With BeneFIX In Chinese Subjects

Completed
NCT00037557Phase 3

Study Evaluating rFIX; BeneFIX in Severe Hemophilia B

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8